Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 131-138

  Kahlert, U D ^a   Nikkhah, G ^a   Maciaczyk, J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cancer stem cell; EMT; GBM; Invasiveness

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; FRIZZLED PROTEIN 4; IMATINIB; MICRORNA; PROTEIN TWIST1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SNAIL1; TRANSCRIPTION FACTOR SNAIL2; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; WNT PROTEIN;

BREAST CARCINOMA; BREAST SARCOMA; CANCER GROWTH; CELL INVASION; CHRONIC MYELOID LEUKEMIA; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SPINDLE CELL SARCOMA;

EID: 84875364615     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.010     Document Type: Review

References (123)

1. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., et al. MiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
3. Asnaghi L., Ebrahimi K.B., Schreck K.C., Bar E.E., Coonfield M.L., Bell W.R., et al. Notch signaling promotes growth and invasion in uveal melanoma. Clin. Cancer Res. 2012, 18:654-665.
4. Bao B., Wang Z., Ali S., Kong D., Li Y., Ahmad A., et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011, 307:26-36.
5. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
6. Bar E.E., Chaudhry A., Lin A., Fan X., Schreck K., Matsui W., et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25:2524-2533.
7. Bar E.E., Lin A., Mahairaki V., Matsui W., Eberhart C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 2010, 177:1491-1502.
8. Bhat-Nakshatri P., Appaiah H., Ballas C., Pick-Franke P., Goulet R., Badve S., et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 2010, 10:411.
9. Bleau A.-M., Huse J.T., Holland E.C. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8:2936-2944.
10. Borovski T., Beke P., van Tellingen O., Rodermond H.M., Verhoeff J.J., Lascano V., et al. Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme. Oncogene 2012.
11. Brabletz S., Bajdak K., Meidhof S., Burk U., Niedermann G., Firat E., et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 2011, 30:770-782.
12. Brabletz T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 2012, 12:425-436.
13. Brabletz T., Jung A., Hermann K., Günther K., Hohenberger W., Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract. 1998, 194:701-704.
14. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Kunz-Schughart L.A., et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 2001, 98:10356-10361.
15. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
16. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121:1064-1074.
17. Bullock M.D., Sayan A.E., Packham G.K., Mirnezami A.H. MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol. Cell 2012, 104:3-12.
18. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
19. Castilla M.á., Moreno-Bueno G., Romero-Pérez L., Van De Vijver K., Biscuola M., López-García M.á., et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J. Pathol. 2011, 223:72-80.
20. Cates J.M.M., Dupont W.D., Barnes J.W., Edmunds H.S., Fasig J.H., Olson S.J., et al. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl. Immunohistochem. Mol. Morphol. 2008, 16:251-262.
21. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108:7950-7955.
22. Chang C.-J., Chao C.-H., Xia W., Yang J.-Y., Xiong Y., Li C.-W., et al. P53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13:317-323.
23. Cheng W.-Y., Kandel J.J., Yamashiro D.J., Canoll P., Anastassiou D. A multi-cancer mesenchymal transition gene expression signature is associated with prolonged time to recurrence in glioblastoma. PLoS ONE 2012, 7:e34705.
24. Cooper L.A.D., Kong J., Gutman D.A., Wang F., Gao J., Appin C., et al. Integrated morphologic analysis for the identification and characterization of disease subtypes. J. Am. Med. Inform. Assoc. 2012, 19:317-323.
25. Cosset E., Hamdan G., Jeanpierre S., Voeltzel T., Sagorny K., Hayette S., et al. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood 2011, 117:1673-1676.
26. Deeken J.F., Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13:1663-1674.
27. Diehn M., Cho R.W., Clarke M.F. Therapeutic implications of the cancer stem cell hypothesis. Semin. Radiat. Oncol. 2009, 19:78-86.
28. Dirks P.B. Brain tumor stem cells: bringing order to the chaos of brain cancer. J. Clin. Oncol. 2008, 26:2916-2924.
29. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.-M., García-Echeverría C., et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 2009, 106:268-273.
30. Edwards L.A., Woolard K., Son M.J., Li A., Lee J., Ene C., et al. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J. Natl. Cancer Inst. 2011, 103:1162-1178.
31. Elias M.C., Tozer K.R., Silber J.R., Mikheeva S., Deng M., Morrison R.S., et al. TWIST is expressed in human gliomas and promotes invasion. Neoplasia 2005, 7:824-837.
32. Evans S.M., Judy K.D., Dunphy I., Jenkins W.T., Hwang W.-T., Nelson P.T., et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 2004, 10:8177-8184.
33. Fan X., Khaki L., Zhu T.S., Soules M.E., Talsma C.E., Gul N., et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 2010, 28:5-16.
34. Fan X., Matsui W., Khaki L., Stearns D., Chun J., Li Y.-M., et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006, 66:7445-7452.
35. Fang L., Deng Z., Shatseva T., Yang J., Peng C., Du W.W., et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene 2011, 30:806-821.
36. Farnie G., Clarke R.B. Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev. 2007, 3:169-175.
37. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 2008, 7:2725-2735.
38. Fenouille N., Tichet M., Dufies M., Pottier A., Mogha A., Soo J.K., et al. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS ONE 2012, 7:e40378.
39. Fortini M.E. Notch Signaling: the core pathway and its posttranslational regulation. Dev. Cell 2009, 16:633-647.
40. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28:5369-5380.
41. Güngör C., Zander H., Effenberger K.E., Vashist Y.K., Kalinina T., Izbicki J.R., et al. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011, 71:5009-5019.
42. Guo Y., Zi X., Koontz Z., Kim A., Xie J., Gorlick R., et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J. Orthop. Res. 2007, 25:964-971.
43. Gupta P.B., Fillmore C.M., Jiang G., Shapira S.D., Tao K., Kuperwasser C., et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011, 146:633-644.
44. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS ONE 2012, 7:e39520.
45. Han S.-P., Kim J.-H., Han M.-E., Sim H.-E., Kim K.-S., Yoon S., et al. SNAI1 is involved in the proliferation and migration of glioblastoma cells. Cell. Mol. Neurobiol. 2011, 31:489-496.
46. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med 2005, 352:997-1003.
47. Henry L.R., Lee H.-O., Lee J.S., Klein-Szanto A., Watts P., Ross E.A., et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin. Cancer Res. 2007, 13:1736-1741.
48. Hide T., Takezaki T., Nakamura H., Kuratsu J., Kondo T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol. 2008, 25:67-72.
49. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
50. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
51. * promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop. J. Clin. Invest. 2012, 122:33-47.
52. Jin X., Jeon H.-Y., Joo K.M., Kim J.-K., Jin J., Kim S.H., et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 2011, 71:3066-3075.
53. U. Kahlert, D. Maciaczyk, S. Doostkam, B.A. Orr, B. Simons, T. Bogiel, et al., Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition, Cancer Lett. 325 (1) (2012) 42-53.(Epub 2012 May 28). http://dx.doi.org/10.1016/j.canlet.2012.05.024.
54. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
55. Kefas B., Comeau L., Erdle N., Montgomery E., Amos S., Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-oncology 2010, 12:1102-1112.
56. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., et al. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572.
57. Kim H.-A., Koo B.-K., Cho J.-H., Kim Y.-Y., Seong J., Chang H.J., et al. Notch1 counteracts WNT/β-catenin signaling through chromatin modification in colorectal cancer 2012, J. Clin., Invest.
58. Kim N.H., Kim H.S., Li X.-Y., Lee I., Choi H.-S., Kang S.E., et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 2011, 195:417-433.
59. Kim T., Veronese A., Pichiorri F., Lee T.J., Jeon Y.-J., Volinia S., et al. P53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J. Exp. Med. 2011, 208:875-883.
60. Koso H., Takeda H., Yew C.C.K., Ward J.M., Nariai N., Ueno K., et al. Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc. Natl. Acad. Sci. USA 2012.
61. de Krijger I., Mekenkamp L.J.M., Punt C.J.A., Nagtegaal I.D. MicroRNAs in colorectal cancer metastasis. J. Pathol. 2011, 224:438-447.
62. Kushiro K., Chu R.A., Verma A., Núñez N.P. Adipocytes promote B16BL6 melanoma cell Invasion and the epithelial-to-mesenchymal transition. Cancer Microenviron. 2012, 5:73-82.
63. Kwak H.-J., Kim Y.-J., Chun K.-R., Woo Y.M., Park S.-J., Jeong J.-A., et al. Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene 2011, 30:2433-2442.
64. Lambiv W.L., Vassallo I., Delorenzi M., Shay T., Diserens A.-C., Misra A., et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro-oncology 2011, 13:736-747.
65. Ledford H. Cancer theory faces doubts. Nat. News 2011, 472:273.
66. Lewis-Tuffin L.J., Rodriguez F., Giannini C., Scheithauer B., Necela B.M., Sarkaria J.N., et al. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS ONE 2010, 5:e13665.
67. Liu F., Gomez Garcia A.M., Meyskens F.L. NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. J. Invest. Dermatol. 2012, 132:2033-2041.
68. Liu Y.-N., Yin J.J., Abou-Kheir W., Hynes P.G., Casey O.M., Fang L., et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene 2012.
69. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
70. Ma X., Yoshimoto K., Guan Y., Hata N., Mizoguchi M., Sagata N., et al. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro-oncology 2012, 14:1153-1162.
71. Mancini M., Petta S., Iacobucci I., Salvestrini V., Barbieri E., Santucci M.A. Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. Cell. Signal. 2010, 22:1247-1253.
72. Mani S.A., Guo W., Liao M.-J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
73. Mikheeva S.A., Mikheev A.M., Petit A., Beyer R., Oxford R.G., Khorasani L., et al. TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol. Cancer 2010, 9:194.
74. Moes M., Le Béchec A., Crespo I., Laurini C., Halavatyi A., Vetter G., et al. A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS ONE 2012, 7:e35440.
75. Mohyeldin A., Garzón-Muvdi T., Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
76. Møller H.G., Rasmussen A.P., Andersen H.H., Johnsen K.B., Henriksen M., Duroux M. A systematic review of MicroRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol. Neurobiol. 2012.
77. Nagaishi M., Paulus W., Brokinkel B., Vital A., Tanaka Y., Nakazato Y., et al. Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathol. 2012, (Zurich, Switzerland).
78. Nicoloso M.S., Calin G.A. MicroRNA involvement in brain tumors: from bench to bedside. Brain Pathol. 2008, 18:122-129.
79. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522.
80. Ohashi S., Natsuizaka M., Naganuma S., Kagawa S., Kimura S., Itoh H., et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. Cancer Res. 2011, 71:6836-6847.
81. Orr B.A., Bai H., Odia Y., Jain D., Anders R.A., Eberhart C.G. Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth. J. Neuropathol. Exp. Neurol 2011, 70:568-577.
82. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
83. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
84. Pistollato F., Abbadi S., Rampazzo E., Persano L., Della Puppa A., Frasson C., et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem cells 2010, 28:851-862.
85. Puissant A., Dufies M., Fenouille N., Ben Sahra I., Jacquel A., Robert G., et al. Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. J. Mol. Cell Biol. 2012, 4:207-220.
86. Purow B., Schiff D. Advances in the genetics of glioblastoma: are we reaching critical mass?. Nat. Rev. Neurol. 2009, 5:419-426.
87. Qi S., Song Y., Peng Y., Wang H., Long H., Yu X., et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE 2012, 7:e38842.
88. Richter C., Oktaba K., Steinmann J., Müller J., Knoblich J.A. The tumour suppressor L(3)mbt inhibits neuroepithelial proliferation and acts on insulator elements. Nat. Cell Biol. 2011, 13:1029-1039.
89. Sánchez-Tilló E., Liu Y., de Barrios O., Siles L., Fanlo L., Cuatrecasas M., et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell. Mol. Life Sci. 2012, 69:3429-3456.
90. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2011.
91. Schreck K.C., Taylor P., Marchionni L., Gopalakrishnan V., Bar E.E., Gaiano N., et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin. Cancer Res. 2010, 16:6060-6070.
92. Seol M.-A., Chu I.-S., Lee M.-J., Yu G.-R., Cui X.-D., Cho B.-H., et al. Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentiation of cholangiocarcinoma. BMC Cancer 2011, 11:78.
93. Shirley S.H., Greene V.R., Duncan L.M., Torres Cabala C.A., Grimm E.A., Kusewitt D.F. Slug expression during melanoma progression. Am. J. Pathol. 2012, 180:2479-2489.
94. Shu M., Zheng X., Wu S., Lu H., Leng T., Zhu W., et al. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Mol. Cancer 2011, 10:59.
95. Siebzehnrubl F.A., Reynolds B.A., Vescovi A., Steindler D.A., Deleyrolle L.P. The origins of glioma: E Pluribus Unum?. Glia 2011, 59:1135-1147.
96. Silber J., Jacobsen A., Ozawa T., Harinath G., Pedraza A., Sander C., et al. MiR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 2012, 7:e33844.
97. Singh A., Settleman J. EMT, cancer stem cells and drug resistance. an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
98. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
99. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med 2005, 352:987-996.
100. Su J., Zhang A., Shi Z., Ma F., Pu P., Wang T., et al. MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin. Int. J. Oncol. 2012, 40:1162-1170.
101. Sulman E.P., Aldape K. The use of global profiling in biomarker development for gliomas. Brain Pathol. 2011, 21:88-95.
102. Sun L., Yan W., Wang Y., Sun G., Luo H., Zhang J., et al. MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res. 2011, 1389:9-18.
103. Sun L., Yao Y., Liu B., Lin Z., Lin L., Yang M., et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2011.
104. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res. 2010, 16:3153-3162.
105. Thiery J.P., Acloque H., Huang R.Y.J., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
106. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.-C., et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9:e1001162.
107. Verhaak R.G.W., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
108. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
109. Wang L., Shi M., Hou S., Ding B., Liu L., Ji X., et al. MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 2012, 586:1312-1317.
110. Weissenberger J., Priester M., Bernreuther C., Rakel S., Glatzel M., Seifert V., et al. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin. Cancer Res. 2010, 16:5781-5795.
111. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
112. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol 2009, 11:1487-1495.
113. Wels C., Joshi S., Koefinger P., Bergler H., Schaider H. Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelial-mesenchymal transition-like phenotype in melanoma. J. Invest. Dermatol. 2011, 131:1877-1885.
114. Winter J., Jung S., Keller S., Gregory R.I., Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11:228-234.
115. Xing F., Okuda H., Watabe M., Kobayashi A., Pai S.K., Liu W., et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 2011, 30:4075-4086.
116. Xu Y., Stamenkovic I., Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010, 70:2455-2464.
117. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
118. Yang M.-H., Wu M.-Z., Chiou S.-H., Chen P.-M., Chang S.-Y., Liu C.-J., et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 2008, 10:295-305.
119. Yu W., Kamara H., Svoboda K.K.H. The role of twist during palate development. Dev. Dyn. 2008, 237:2716-2725.
120. Yue X., Wang P., Xu J., Zhu Y., Sun G., Pang Q., et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol. Rep. 2012, 27:1200-1206.
121. Zhang H., Li Y., Lai M. The microRNA network and tumor metastasis. Oncogene 2010, 29:937-948.
122. Zhao B., Tumaneng K., Guan K.-L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 2011, 13:877-883.
123. Zinn P.O., Mahajan B., Majadan B., Sathyan P., Singh S.K., Majumder S., et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS ONE 2011, 6:e25451.